Hematopoietic growth factors in the older cancer patient

Current Opinion in Hematology

Volumn 8, Issue 3, 2001, Pages 170-187

  Balducci, Lodovico ^a   Hardy, Cheryl L ^b,c   Lyman, Gary H ^b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; BIRTH RATE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; DECISION MAKING; DRUG COST; DRUG EFFICACY; HEMATOPOIESIS; HUMAN; LIFE EXPECTANCY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; STRESS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONY-STIMULATING FACTORS; HEMATOPOIESIS; HUMANS; NEOPLASMS;

EID: 0035055406     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200105000-00008     Document Type: Review

References (155)

1. Physiology of aging: Relevance to symptom perceptions and treatment tolerance
2. Antineoplastic chemotherapy of the older cancer patient
3. Cancer in the older persons magnitude of the problem - How we apply what we know?
4. Hemopoietic reserve in older cancer patients: Clinical and economical considerations
5. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice
6. Stem cells and genetics in the study of development, aging and longevity
7. Age-related decline in hemopoietic reserve capacity
8. Hematopoiesis and cytokines. Relevance to cancer and aging
9. The aging bone marrow
10. Management of Infectious Complications
11. Effects of "in vivo" recombinant methionyl human granulocyte colony-stimulating factor on the immune response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers
12. Incidence of anemia in older people: An epidemiologic study of a well defined population
13. Anemia in elderly patients. Incidence and causes of low hemoglobin concentration in a city general practice
14. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly
15. Colony stimulating factors (CSFs) may reduce complications and death in solid tumor patients with fever and neutropenia
16. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocytemacrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
17. Evidence for a continuous decline in hemopoietic cell function from birth: Application to evaluating bone marrow failure in children
18. Hemopoiesis in healthy old people and centenarian; well maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network
19. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: Some results of an Italian multicentric study
20. Hematopoiesis in the aged: A model of hematopoietic dysregular
21. The expression of granulocyte/macrophase colony-stimulating factor in activated mouse lymphocytes declines with age
22. Anemia of aging: A model of cancer-related anemia
23. An inappropriate erythropoietic response to iron deficiency anemia in the elderly
24. Reduced erythropoietin secretion in senile anemia
25. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: The effects of age and gender
26. Haematological abnormalities and reference intervals in the elderly. A cross-sectional comparative study of three urban Swedish population samples aged 70, 75 and 81 years
27. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin
28. Iron and erythropoietin measurements in autologous blood donors with anemia: Implications for management
29. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia
30. Age-related changes in myelopoietic response to lipopolysaccaride in senescence-accelerated mice
31. Frailty and the the somatopause
32. Emerging evidence for inflammation in conditions frequently affecting older adults: Report of a symposium
33. The immune-endocrine loop during aging: Role of growth hormone and insuline-like growth factor1
34. Hematopoiesis and aging III: Anemia and a blunted Erythropoietic response to hemorrage in aged mice
35. Defective burst-promoting activity of T lymphocytes from anemic and non-anemic elderly people
36. Hematopoiesis in the aged as studied by "in vitro" colony assay
37. Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia
38. Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly
39. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors
40. nd: Tolerabitity and side-effect profile of rhlL-11
41. Effects of megakaryocyte growth and development factor on platelet production, platelet life span and platelet function in healthy human volunteers
42. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia
43. Multiple myeloma
44. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group
45. Cyclophosphamide, Methotrexate and 5Fluorouracil chemotherapy in women more than 65 year old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance
46. Chemotherapy of metastatic breast cancer in the Elderly
47. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois Cancer Center Study
48. Doxorubicin based combination chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome
49. Doxorubicin based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson Experience with long term follow-up
50. A prospective pharmacologic evaluation of age-related toxicity and adjuvant chemotherapy in women with breast cancer
51. Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: "More" or "less" better?
52. Elderly aggressive histology Non-Hodgkin's Lymphoma: First Line VNCOP.B Regimen: Experience on 350 patients
53. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy
54. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate and high grade Non-Hodgkin's lymphoma: Results of a randomized study of the European organization for the Research and Treatment of Cancer Lymphoma Cooperative Study
55. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment and survival
56. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a Phase II study of P/DOCE chemotherapy
57. Treatment of acute myelogenous leukemia in older adults
58. Acute Myelogenous Leukemia and aging: Clinical Interactions
59. Impact of therapy with epoietin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practices
60. Quality of life benefits in chemotherapy patients treated with epoietin alfa is independent from disease response and tumor type. Result of a prospective community oncology study
61. Fatigue in an older population
62. Importance of functional measures in predicting mortality among older hospitalized patients
63. Comprehensive Geriatric Assessment in a day hospital
64. Validation of a multidimensional evaluation scale for use in elderly cancer patients
65. Identifying hemoglobin levels for optimal Quality of Life. Results of an incremental analysis
66. Once weekly dosing of epoietin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life
67. Delirium is independently associated with poor functional recovery after hip fracture
68. Erythropoietin addition to granulocytecolony stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin in combination chemotherapy
69. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability
70. First-cycle Blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy
71. Role of red blood cell in pharmakinetics of chemotherapeutic agents
72. Epidemiology of sarcopenia
73. The predictive value of body proteins for chemotherapy induced toxicity
74. Effect of age on therapeutic outcome in advanced diffuse hisiocytic lymphoma: The Southwest oncology group experience
75. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's Lymphoma
76. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CHOIP treatment of elderly patients with aggressive non-Hodgkins lymphoma. Proc ASH
77. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
78. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group
79. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
80. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non-lymphocytic leukemia: Results of the L16M protocol
81. A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55-70 years) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E3993)
82. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly
83. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes
84. Intensive postremission chemotherapy in adult with acute myeloid leukemia
85. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies with cytogenetics subtype
86. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalationof doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC)
87. Increased intensification and total dose of cyclophosphamide in doxorubicin-cyclophosphamide regimen for the treatment of breast cancer: Findings from National Surgical Adjuvant Breast Bowel Project B-22
88. Dose and dose intensity of adjuvant chemotherapy for stage II positive breast carcinoma
89. Dose calculations of anticancer drugs: A review of the current practice and introduction of an alternative
90. Management of cancer in the older person: A practical approach
91. A brief duration combination chemotherapy for elderly patients with poor prognosis non-Hodgkin's Lymphoma
92. The prophylaxis of bacterial infections in neutropenic patients
93. Recombinant hemopoetic growth factors: Comparative hemopoietic response in younger and older subjects
94. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans
95. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with Non-Hodgkin's lymphoma treated with combination chemotherapy
96. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasiblity and efficacy of an intensive multidrug regimen
97. Randomized placebo-controlled phase III study of Granulocyte-macrophage Colony Stimulating factor in adult patients (>55-70 years with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
98. A randomized double blind placebo controlled phase III study of filgrastim in remission induction and consolidation therapy for patients with "de novo" acute myeloid leukemia
99. Use of recombinant GM-CSF during and after remission-induction chemotherapy in patients aged 61 and older with acute non-lymphocytic leukemia: Final report of AML-11 a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hematology Oncology Cooperative Group
100. Granu, ocyte-macrophage colony stimulating factor associated induction treatment of acute myelogenous leukemia: A randomized study by the European Organization for Research and Treatment of leukemia Cooperative Group
101. A placebo-controlled study of recombinant human granulocyte macrophage colony-stimulating factor administered during an induction treatment for "de novo" acute myelogenous leukemia in older patients
102. Granulocyte-macrophage Colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
103. A controlled study of recombinant Human granulocyte Colony-Stimulating factor in elderly patients after treatment for acute myelogenous leukemia
104. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
105. A double blind placebo controlled trial of Granulocyte Colony-Stimulating factor in Elderly patients with previously untreated acute myelogenous leukemia
106. Treatment of Acute Myeloid leukemia with cytokines. Efffects on duration of neutropenia and response to infection
107. Erythropoietin therapy in chronic uremia: The impact of norm of hematocrit
108. Pathogenesis and treatment of the anemia of chronic disease
109. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
110. Cytokine therapy for myelodysplastic syndrome
111. Recominant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma
112. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
113. Cost-effectiveness and quality of life assessment of GM-CSF as an adjunct to intensive remission-induction chemotherapyin elderly patients with acute myeloid leukemia
114. Hempoietic alterations of cancer
115. Energy metabolism in sepsis and injury
116. General guidelines for the management of cancer in the elderly
117. The purpose of advanced medical planning: Autonomy for patients or limitations of care
118. Modeling programme cost in economic evaluation
119. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
120. Integrating Economic analysis into cancer clinical trials: The national Cancer Institute-American Society of Clinical Oncology workbook
121. Cost of outpatient blood transfusions in cancer patients
122. Decision Analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
123. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
124. New trends in patient management: Risk-based therapy for febrile patients with neutropenia
125. Granulocyte colony-stimulating factor in severe chemotherapy-induced abebrile neutropenia
126. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
127. Impact of cancer-related fatigue on the lives of patients
128. Cancer and aging: An evolving panorama
129. A brief instrument to classify frailty in elderly people
130. Toward an understanding of frailty
131. Money, Medicine and Metusalah
132. Disease, disability, and age in cognitively intact seniors: Results from the Canadian Study of health and aging
133. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery
134. The redox status as a correlate of senescence and wasting and as a target for therapeutic intervention
135. The process of care in preventive "in home" comprehensive geriatric assessment
136. Randomised trial of impact of model of integrated care and case management for older people living in the community
137. Interventions to reduce the incidence of falling in the elderly
138. A multicomponent intervention to prevent delirium in hospitalized older patients
139. Functional impairment in Instrumental Activities of Daily Living: An early clinical sign of dementia?
140. Measurement and impact of comorbidity in older cancer patients
141. Measuring comorbidity in older cancer patients
142. The family caregiver of the older cancer patient
143. A Mini Mental State: A practical method for grading the cognitive status of patients for the clinician
144. The effect of cognitive impairment on 9-year mortality in a community sample
145. Psychiatric Status and nine year mortalitydata in the new haven Epidemiologic catchment Area Study
146. The effects of falls and fall injuries in functioning in community dwelling older persons
147. Failure to thrive in old age: Follow-up on a workshop
148. The high prevalence of depression and dementia in elder abuse or neglect
149. Mortality of elder mistreatment
150. The application of geriatric principles to the management of the older cancer patient
151. Comorbidity and functional status are independent in older cancer patients
152. Mininutritional assessment: A practical assessment tool for grading the nutritional state of elderly patients
153. Polypharmacy in the older patient